Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After
Johnson & Johnson (JNJ) reported Q3 non-GAAP EPS of $2.59, beating estimates by $0.06. The company raised its 2026 sales forecast to $101.2B and adjusted EPS guidance to $11.10. Shares gained 1% in after-hours trading. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a 4.9% 3-year dividend growth rate. The company's GF Score™ is 83/100, reflecting strong financial health and growth prospects. Insider activity shows significant net selling over the past 12 months.
How this was made
The 30-second read
Why it matters
Guidance lift could attract income investors and boost dividend‑oriented ETFs.
Market read
First‑report earnings and guidance update for a mega‑cap health stock, likely to move the ticker and related sector funds.
What to watch
Insider net selling and mixed guru sentiment could temper enthusiasm.
Background
Johnson & Johnson reported Q3 results, beating EPS expectations and raising full‑year guidance.
Ticker impact
Q3 non‑GAAP EPS beat and 2026 sales/adjusted EPS guidance raised, driving a 1% after‑hours price gain.
upward pressure as investors price in higher sales and EPS forecasts
Earnings beat and guidance raise are fresh, material data for a large‑cap health stock.
Market effects
May lift broader healthcare and dividend‑focused funds as JNJ signals stronger demand.
U.S. market sentiment could improve modestly in early trading.
Reinforces confidence in global pharma demand, but limited outside U.S. equities.
Counterpoint
Valuation remains premium; investors may wait for price correction before buying.
Key entities
- companyJohnson & Johnson
Global healthcare conglomerate (ticker JNJ).
